- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
27 result(s) found for: MLL.
Displaying page 1 of 2.
EudraCT Number: 2014-003647-34 | Sponsor Protocol Number: AMLSG23-14/Palbo-AL-1 | Start Date*: 2015-05-19 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias | ||
Medical condition: Acute myeloid leukemia Acute lymphoblastic leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006931-11 | Sponsor Protocol Number: CPKC412A2114 | Start Date*: 2009-11-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynami... | |||||||||||||
Medical condition: in pediatric patients with relapsed or refractory leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004674-17 | Sponsor Protocol Number: NL59901.078.17 | Start Date*: 2017-10-17 | |||||||||||
Sponsor Name:Princess Máxima Center for Pediatric Oncology | |||||||||||||
Full Title: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) BE (Completed) DK (Completed) DE (Completed) CZ (Completed) FR (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004021-19 | Sponsor Protocol Number: NOPHO ALL 2008 pilot | Start Date*: 2008-03-25 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: NOPHO ALL-2008 PILOT STUDY ON CONSOLIDATION THERAPY FOR CHILDREN AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA | |||||||||||||
Medical condition: Acute lymphoblastic leukemia in children 1.0-18 years of age | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002933-36 | Sponsor Protocol Number: ALFA-0701 Study (Mylofrance 3) | Start Date*: 2007-11-02 |
Sponsor Name:CH-Versailles | ||
Full Title: Etude de phase 3 randomisée multicentrique étudiant l’effet de l’addition de l’anticorps monoclonal Gemtuzumab Ozogamicin (Mylotarg) utilisé en doses fractionnées au traitement d’induction et de co... | ||
Medical condition: The standard regimen for AML is the with Mylotarg, 3 mg/m2 given on days 1,4 and 7. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003353-16 | Sponsor Protocol Number: GS-US-339-1559 | Start Date*: 2017-04-18 |
Sponsor Name:Gilead Sciences, Inc | ||
Full Title: A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML) | ||
Medical condition: Acute Myeloid Leukemia (AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000668-18 | Sponsor Protocol Number: 2006.456/50 | Start Date*: 2009-01-20 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA) versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients with Newly-Diagnosed Acute Myeloid Leu... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005562-39 | Sponsor Protocol Number: P060205 | Start Date*: 2008-08-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: ALFA 0703 : A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Chemotherapy or azacitidine as salvage therapy and Azacitidine as Mai... | |||||||||||||
Medical condition: Older patients with acute myeloblastic leukemia (AML). | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001082-15 | Sponsor Protocol Number: IPC2006-07 | Start Date*: 2008-07-31 | |||||||||||
Sponsor Name:Institut Paoli Calmette | |||||||||||||
Full Title: Etude de Phase I-II multicentrique de l'association Cloretazine-Daunorubicine-Aracytine dans le traitement des leucémies aigües myéloïdes du groupe cytogénétique défavorable. | |||||||||||||
Medical condition: Malades atteints de Leucémie Aigüe Myéloïde | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004599-19 | Sponsor Protocol Number: INTERFANT-06 | Start Date*: 2005-11-24 | |||||||||||
Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA | |||||||||||||
Full Title: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA | |||||||||||||
Medical condition: acute lymphoblastic leukemia (ALL) or biphenotypic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) BE (Completed) FR (Ongoing) DE (Completed) GB (Completed) AT (Ongoing) PT (Completed) DK (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000442-21 | Sponsor Protocol Number: RC17_0029 | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: Effects of perioperative administration of dexamethasone on postoperative complications and mortality after non-cardiac major surgery : a randomized, multicentre, double blind, study | |||||||||||||
Medical condition: non-cardiac major surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001545-41 | Sponsor Protocol Number: KO-MEN-001 | Start Date*: 2021-09-09 | |||||||||||
Sponsor Name:Kura Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | |||||||||||||
Medical condition: Relapsed and/or refractory Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003452-32 | Sponsor Protocol Number: CD19-CAR_Lenti | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma... | |||||||||||||
Medical condition: relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma or Primary Mediastinal B Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004877-42 | Sponsor Protocol Number: PETHEMA-BLIN-01 | Start Date*: 2018-04-25 | |||||||||||
Sponsor Name:FUNDACIÓN PETHEMA | |||||||||||||
Full Title: A phase II, open-label study to evaluate the effect of blinatumomab administered during consolidation to reduce the level of minimal residual disease (MRD) assessed through flow cytometry in adult ... | |||||||||||||
Medical condition: Acute lymphoblastic leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000018-39 | Sponsor Protocol Number: AMLBFM2012 | Start Date*: 2014-11-20 | |||||||||||
Sponsor Name:Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH gGmbH) | |||||||||||||
Full Title: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents | |||||||||||||
Medical condition: AML | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002146-44 | Sponsor Protocol Number: P120139 | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004104-34 | Sponsor Protocol Number: SNDX-5613-0700 | Start Date*: 2022-04-20 | |||||||||||
Sponsor Name:Syndax Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nu... | |||||||||||||
Medical condition: Relapsed or Refractory Acute Leukemias | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) DE (Temporarily Halted) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005535-90 | Sponsor Protocol Number: BHS-TC-10 | Start Date*: 2013-12-09 | ||||||||||||||||
Sponsor Name:CHU Mont-Godinne | ||||||||||||||||||
Full Title: Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogenei... | ||||||||||||||||||
Medical condition: Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002934-35 | Sponsor Protocol Number: 2.1 | Start Date*: 2013-01-22 | |||||||||||
Sponsor Name:Västra Götaland Regionen | |||||||||||||
Full Title: NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years | |||||||||||||
Medical condition: Acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001209-64 | Sponsor Protocol Number: BRD 06/10-I | Start Date*: 2007-08-16 | |||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Nantes | |||||||||||||
Full Title: Etude multicentrique de phase III randomisée ouverte testant l’efficacité du gemtuzumab ozogamycin (MYLOTARG®) en association avec la chimiothérapie intensive chez les patients de 18 à 60 ans attei... | |||||||||||||
Medical condition: leucémie aiguë myéloblastique (LAM) avec cytogénétique intermédiaire | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
